Gustavo Viani: Neoadjuvant immunotherapy for unresectable stage III NSCLC followed by CRT
Gustavo Viani shared a post on LinkedIn about a recent paper by Helen Ross et al. published in
Authors: Helen Ross, David Kozono, Xiaofei Wang, Everett Vokes, Thomas Stinchcombe et al.
“Good results with neoadjuvant immunotherapy for unresectable stage III NSCLC followed by CRT! Randomized clinical trials are needed!
Study Design: Phase II, single-cohort trial with 62 with unresectable stage III NSCLC.
- Intervention: Atezolizumab given before and after chemoradiation therapy (CRT)
- Outcome: Disease control rate at 12 weeks was 74.2%
Results:
- Median PFS 30 m / OS at 24 months 73.7%
- Adverse Events:27.4% grade 3+ immune-related events, including pneumonitis and Guillain-Barré syndrome.”
Source: Gustavo Viani/LinkedIn
More posts featuring Gustavo Viani on oncodaily.com
Gustavo Viani, MD is an Associate Professor in the Department of Medical Imaging, Hematology, and Oncology at Hospital das Clínicas, Faculty of Medicine of Ribeirão Preto, University of São Paulo (FMRP-USP). Dr. Viani’s research focuses on radiation oncology, with expertise in brachytherapy, stereotactic radiosurgery, dose fractionation, radiation tolerance, and overall oncology practices.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023